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Abstract
Purpose:

Examine the relationships between high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and soluble tumor necrosis factor-α receptor-1
(sTNF-R1) and the cumulative risk of heart failure with reduced (HFrEF)
and preserved (HFpEF) ejection fractions in a diverse, population-based
sample.

Methods:

Study sample included 6,814 adult (45-84 years of age) men and women
who participated in the Multi-Ethnic Study of Atherosclerosis and were free
of cardiovascular disease at baseline. Cox regression was used to calculate
the hazard ratios (HR) associated with elevated baseline hs-CRP (> 3-10
mg/L), IL-6 (> 75th percentile) and sTNF-R1 (> 75th percentile) and risk of
overall HF, HFrEF (ejection fraction [EF] < 50%), and HFpEF (EF ≥ 50%).

Results:

During ~11.2 years of follow-up there were 178 incident HF diagnoses.
Elevated hs-CRP, IL-6 and sTNF-R1 were associated with a significant
increased risk of HF overall (HR 1.76; 95% Confidence interval [CI] 1.222.52, HR 1.57; 95% 1.07-2.30, and HR 1.91; 95% CI 1.08-3.38,
respectively). Elevated hs-CRP was a significant predictor in both HFrEF
and HFpEF (HR 2.05; 95% CI 1.26-3.35, and HR 1.89; 95% CI 1.09-3.28,
respectively). Baseline IL-6 concentrations were significantly associated
with increased risk of HFrEF in nonsmokers only (HR 2.33; 95% CI 1.045.23) and of HFpEF in African Americans only (HR 5.89; 95% CI 1.5222.80).

XII
Conclusion:

In a diverse sample of U.S. adults, elevated hs-CRP, IL-6 and sTNF-R1 were
significant predictors of HF. Furthermore, both hs-CRP and IL-6 were
significant predictors in HFrEF and HFpEF.
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Chapter One: Introduction

2
Heart failure (HF) is a condition characterized by an inability of the heart to supply
sufficient blood to the body to meet metabolic demands or accommodate systemic venous return
(1). This disease manifests either due to failure of the left ventricle (LV) to fill with enough
blood or to contract with enough force or, occasionally, a combination of the two (2, 3). The
inability to contract with sufficient force often results in a reduced percentage of blood ejected
from the LV, also known as the ejection fraction (EF). These patients are considered to have
heart failure with reduced ejection fraction (HFrEF). Those with an inability to properly fill the
LV can often still eject a volume of blood that is proportional to their end diastolic volume,
resulting in a normal, or preserved, EF. Accordingly, these patients are considered to have heart
failure with preserved ejection fraction (HFpEF). Although these subtypes share several
similarities, recent literature has demonstrated distinct differences in the epidemiology, etiology,
treatment, and prognosis (4, 5) of HFrEF and HFpEF. Chronic inflammation, characterized using
several different inflammatory biomarkers, has been positively associated with HF incidence,
severity, and prognosis. These biomarkers include C-reactive protein (CRP), interleukin-6 (IL-6),
and soluble tumor necrosis factor- receptor-1 (sTNF-R1) (6–10).
This chapter includes relevant background information pertaining to HF, CRP, IL-6, and
sTNF-R1. This is followed by a focused review of the existing literature regarding the
relationship between these variables. The chapter concludes with the purpose and significance of
the research, a project description, and limitations inherent to the study design.
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BACKGROUND
HEART FAILURE
The prevalence of HF in the adult population ranges from 1 to 3% (5, 11–13) but
increases to upwards of 10% in older populations (13–15). The prevalence of HFpEF among
those with HF varies widely depending on several factors including the diagnostic criteria,
clinical setting, age and sex of the population, and year of publication (2). Nonetheless, most
investigations have found the prevalence of HFpEF in this population is about 50% (16–20).
The age- and sex-adjusted incidence of HF declined 37% from 2000 to 2010 with a much
greater rate reduction seen in those with HFrEF (-45%) than HFpEF (-28%) (P for interaction =
=0.08) (21). However, the prevalence of HF is expected to increase 23% equating to a 46%
increase in the number of Americans living with HF from 2012 to 2030 (22). The increasing
prevalence is largely due to the growth of the aging population as well as improvements in lifeprolonging HF therapy (2, 11, 23). Despite these advancements, mortality rates remain high at
about 19.9 per 100,000 (24) with little or no improvement over the past couple of decades and a
5-year survival rate of ~50% (21, 25, 26).
Though it is believed the first case of HF was identified roughly 3,500 years ago, it was
not until the 1950’s that the idea of cardiac contractility came about and was later believed to
account for changes observed in HF (27). Research then focused on understanding reduced
contractility and developing ionotropic medications that would increase EF in these patients.
Until the late 1980-1990’s, LV systolic dysfunction was considered a prerequisite for HF
however, repeated observations of HF without LV systolic dysfunction lead to the recognition of
heart failure with LV diastolic dysfunction (5, 27–29). The two subtypes were originally termed
systolic and diastolic HF however, the preferred terminology today is HFrEF and HFpEF,
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respectively, as many HF patients demonstrate some degree of both systolic and diastolic
dysfunction (2, 3) but can still be distinguished by left ventricular ejection fraction (LVEF) (3,
4).
Despite the recognition of two distinct HF subtypes over two decades ago, a harmonious
definition for HFrEF and HFpEF has yet to be established (2, 3, 30). In the most recent guideline
for the management of HF (3) set out by the American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA), HF was defined as, “a complex clinical syndrome
that results from any structural or functional impairment of ventricular filling or ejection of
blood.” Impairments that may lead to HF include, but are not limited to, abnormalities of the
myocardium, endocardium, pericardium, heart valves, great vessels, or some metabolic
abnormalities. However, most symptomatic patients have LV myocardial dysfunction. The
ACCF/AHA also emphasized that LV dysfunction and cardiomyopathy are not interchangeable
with HF but instead they should be used to describe possible reasons for the development of
systolic or diastolic LV dysfunction. In the literature, HF subtypes have been classified by
various LVEF cutpoints however, the most recent definition from the ACCF/AHA classifies
HFrEF as an EF ≤ 40% and HFpEF as an EF ≥ 50%. Ejection fraction values ranging from 4149% are considered heart failure with mid-range ejection fraction (HFmrEF).
Though useful for defining HFrEF and HFpEF, more is required for a diagnosis than EF.
Several epidemiological studies have developed their own diagnostic criteria for diagnosing HF
that have continued to be used throughout the years (31–34). These criteria include a
combination of determinants include signs and symptoms, medical history review, radiographic
evidence, and response to therapy however, they do not differentiate between HFrEF and
HFpEF. In response, studies that have aimed to differentiate between HFrEF and HFpEF have
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modified the previously existing criteria to include an EF cut point (29). Several serological
markers, including biomarkers of inflammation, have been implicated to strengthen the HF
diagnosis however; there is a need to investigate novel biomarkers for the evaluation and
management of patients with HF, particularly in HFpEF (35–37).

INFLAMMATORY BIOMARKERS
C-Reactive Protein
C-reactive protein (CRP) is an acute phase plasma protein produced by the liver in
response to inflammation (38). Activation of CRP in hepatocytes is primarily regulated at the
transcriptional level by interleukin-6 (IL-6) but interleukin-1 (IL-1) and tumor necrosis factor-α
(TNF-α) can also regulate CRP to some degree (38–40). There is also evidence of extrahepatic
production of CRP by lymphocytes, neurons, renal cells and in the atherosclerotic lesion,
specifically by smooth muscle and macrophages (39, 41).
In adults with no prior history of cardiovascular disease, a single, non-fasting measure of
CRP can be a strong predictor of future vascular events even after controlling for traditional risk
factors including age, smoking, cholesterol, blood pressure, and diabetes (42). C-reactive protein
has been shown to contribute to atherogenesis and predict incident myocardial infarction, stroke,
peripheral artery disease, and sudden death (39, 42). “High-sensitivity” assays are recommended
for the measurement of CRP as these are designed to detect CRP concentrations across a lownormal range and are widely available (42).
In a 2003 statement (43), the Centers for Disease Control and the AHA recommended
using a high-sensitivity C-reactive protein (hs-CRP) cut point of > 3 mg/L to define high risk in
the adult population. Being a biomarker of inflammation, CRP concentrations can be elevated
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over 100-fold in the presence of major infections, trauma, or acute hospitalizations. For this
reason, it is also recommended that concentrations > 10 mg/L should be discarded.
Interleukin-6
Interleukin-6 (IL-6) is a proinflammatory cytokine secreted by various cells including
activated macrophages and lymphocytes (40). Most cytokines function at the paracrine/autocrine
level however, IL-6 is unique in that it is predominately a circulatory molecule therefore its
major actions take place away from its site of origin. Secretion and expression of IL-6 is induced
by IL-1 and TNF-α (44) and IL-6 can, in turn, regulate the activity of IL-1 by directly inducing
the release of its receptor antagonist and TNF-α. Circulating concentrations of IL-6 increase with
obesity and in the presence of systemic infection or inflammation (40, 45). In healthy
individuals, as much as one-third of total circulating IL-6 concentrations are estimated to
originate from adipose tissue.
Interleukin-6 is sometimes referred to as a “remodeling” biomarker as it can directly
affect cell-to-cell communication between myocytes and fibroblasts, and changes in
concentration are associated with changes in cardiac extracellular matrix and function (37). In a
prospective study of older adults without baseline cardiovascular disease (10), IL-6 was a
significant predictor of incident coronary heart disease, stroke, and congestive HF.
Immunosorbent assays are often used to measure IL-6 levels and high risk is often determined by
the sample-specific upper tertile (9, 10, 46).
Soluble Tumor Necrosis Factor-α Receptor-1
Tumor necrosis factor-α is the smaller and more abundant isoform of tumor necrosis
factor. It is a proinflammatory cytokine produced primarily by macrophages in response to
inflammation however, adipocytes have also been shown to express TNF-α (47). Two distinct
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surface receptors, TNFR-1 and TNFR-2, mediate the effects of TNF and exist in either
membrane-bound or soluble forms (48). Though the extracellular domains of these receptors are
conserved, the cytoplasmic portions are not, suggesting differing downstream processes. Both
receptors have been found in human myocytes with TNFR-1 being the predominate subtype in
most cells, including the heart (48, 49). Binding of TNF-α to TNFR-1 induces an inflammatory
response in the myocytes. Additionally, the extracellular portion of the receptor can then be
cleaved by a proteolytic enzyme, releasing soluble tumor necrosis factor-α recptor-1 (sTNF-R1)
which can then diffuse into circulation (36). Elevated sTNF-R1 has been significantly associated
with an increased risk of HF across whites and blacks, and males and females (50).

FOCUSED LITERATURE REVIEW
Although existing literature has demonstrated an increased risk of HF in those with
elevated hs-CRP (51, 52), IL-6 (9, 51) and sTNF-R1 (50), there are fewer investigations that
have determined these relationships in HFrEF and HFpEF. Furthermore, there is limited data
examining these relationships in multi-ethnic, diverse samples.

PURPOSE AND SIGNIFICANCE
The purpose of this study was to examine the relationship between elevated hs-CRP, IL-6,
and sTNF-R1 and the cumulative risk of HFrEF and HFpEF in a diverse sample of U.S. adults
45-84 years of age. The specific research question addressed was:
1. Is there an association between elevated hs-CRP, IL-6, or sTNF-R1 and the cumulative
risk of HFrEF or HFpEF?
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To the extent of our knowledge, this is the first study to examine the relationship between
elevated hs-CRP, IL-6 and sTNF-R1 and incidence HFrEF and HFpEF in a diverse sample of
U.S. adults 45-84 years of age who participated in the Multi-Ethnic Study of Atherosclerosis
(MESA).

PROJECT DESCRIPTION
The MESA (53) is a community-based, multi-center, prospective cohort study including
6,814 men and women 45-84 years of age who were free of clinical cardiovascular disease at
baseline. Multivariable hazard ratios were calculated using the proportional hazards regression
procedure to determine the cumulative risk of HFrEF and HFpEF according to baseline hs-CRP,
IL-6 and sTNF-R1. Limitations include:
1. Biomarkers of inflammation were measured at a single time point; therefore, it is unclear
if elevated concentrations were indicative of acute or chronic inflammation.
2. Inherent in the design of the MESA, the diverse, multi-ethnic sample was not
representative of the U.S. population, affecting the generalizability of the results.
3. The sample size of those with HF was relatively small, especially when categorized by
HFrEF and HFpEF. Additionally, sample sizes were even smaller for variables such as
sTNF-R1 in which concentrations were only analyzed in a subset of the sample.
4.

Self-reported data was used for some of the covariates which is subject to recall bias and
self-report bias.

5. There is a potential for residual confounding in which there may be additional
confounding factors that were not included.
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6. Incident HF was defined as time to first HF event, therefore subsequent HF events and
potential changes in EF over time were not included in the analysis.
7. Individuals without sufficient EF data at the time of their first HF event were not
included in the analyses.
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Heart failure (HF) is a complex clinical syndrome characterized by an inability of the
heart to deliver enough blood to meet metabolic demands or doing so only at the cost of
increased filling pressures (1, 2). This results from injury or stress to the myocardium which
often occurs due to ischemic heart disease, hypertension, chronic obstructive pulmonary disease,
rheumatic heart disease and diabetes (3, 4). When the heart fails to compensate for injury, signs
and symptoms of HF that develop include dyspnea, fatigue, and fluid retention leading to
pulmonary congestion and/or peripheral edema (2, 5). Though commonly associated with
congestion, exercise tolerance is often limited in HF patients with and without evidence of fluid
retention (2). Underlying abnormalities of the myocardium are common in HF and often result in
left ventricular (LV) systolic and/or diastolic dysfunction, however, abnormalities of the
pericardium, endocardium, heart rhythm, and conduction are also observed (5, 6). One of the
most common noninvasive techniques used to determine the presence of LV systolic or diastolic
dysfunction is by Doppler echocardiography (7). Also, this method is often used to determine left
ventricular ejection fraction (LVEF).
Ejection fraction (EF) refers to the ratio of stroke volume to ventricular-end diastolic
volume (8). This measurement is often used as a quantitative measurement of left ventricular
function and is positively associated with survival in HF patients (9). Although right ventricular
function is also of concern when evaluating HF patients, isolated right-sided HF is uncommon
(10). Furthermore, the most common manifestation of right-sided HF is due to left-sided HF and
it is recommended that these patients be managed as left-sided HF patients. In the most recent
guidelines for the management of HF (2), the American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA), define subtypes of left-sided HF by LVEF. These
subtypes include heart failure with reduced ejection fraction (HFrEF) (EF ≤ 40%), heart failure
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with preserved ejection fraction (HFpEF) (EF ≥ 50%) and heart failure with mid-range ejection
fraction (HFmrEF) (EF 41-49%).
This chapter includes a focused review on HF terminology as well as the two most
prevalent HF subtypes, HFrEF and HFpEF. Existing literature that has investigated the
relationship between high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) or soluble
tumor necrosis factor-α receptor-1 (sTNF-R1) and HF overall, HFrEF or HFpEF are also
included. It concludes with a summary of the literature and the explanation of the need for
additional research.

TERMINOLOGY
Until the 1980-1990’s, other than a few rare cases, HF was believed to occur exclusively
in those with systolic dysfunction (11, 12). In fact, early drug trials in HF that sought to establish
a medication that would improve adverse outcomes in this population either included only those
with a reduced EF or did not differentiate by EF (5, 12). Over time, the repeated observation that
there were individuals with signs and symptoms of HF but without overt reduced systolic
dysfunction lead to the discovery of HF with diastolic dysfunction (1, 12). These two subtypes
were accordingly named systolic heart failure (SHF) and diastolic heart failure (DHF). Although
these terms seemed fitting at the time, it was soon discovered that LV systolic and LV diastolic
dysfunction are not mutually exclusive with many HF patients exhibit some degree of both (2, 5,
13). For this reason, the preferred terminology today is heart failure with reduced ejection
fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Terminology referring to HF overall has also changed over the years. Because pulmonary
congestion has been long recognized as a cardinal sign of HF, the term congestive heart failure
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(CHF) is frequently used interchangeable with HF. Although CHF may accurately describe some
HF patients, it is not always accurate as some patients present without signs or symptoms of
volume overload (2). Furthermore, CHF may be misleading because this acronym is also used to
refer to chronic heart failure rather than congestive heart failure (14). For these reasons, “heart
failure” is the preferred terminology over “congestive heart failure” (2).
It is also of note that the 2013 ACCF/AHA Guideline for the Management of HF (2)
emphasized that cardiomyopathy and LV dysfunction are not synonymous with HF. Instead,
these terms should be used to describe possible reasons for the development of structural and
functional abnormalities in HF.

DIAGNOSIS
Consistent with HF being termed a clinical ‘syndrome’ in the 1990’s, no single sign,
symptom, or clinical history item alone is used to diagnose HF but rather a combination of
several criteria is required (2, 15). Currently, a national or international consensus on a set of
diagnostic criteria for HF does not exist (2, 16). Instead, HF is often a diagnosis of exclusion
following a close medical history review and physical examination (2). In light of the fact that
there is not a single harmonious definition, many epidemiological, clinical, and communitybased studies have created their own criteria or used criteria produced by various organizations
to diagnose HF. Commonly used criteria include the Framingham criteria (17), Gothenburg
criteria (18), Boston criteria (19) , and the Cardiovascular Health Study (CHS) (20) criteria, all of
which rely on a combination of medical history review, signs and symptoms, radiographic
evidence, and response to therapy. Overall, these criteria produce similar estimates, (21)
however, they were not designed to differentiate by HFrEF and HFpEF. The Framingham
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criteria is one of the most widely used and validated of them all. It has been shown to be very
sensitive (92%) and moderately specific (79%) for the diagnosis of HF (22). Specifically,
absence of the Framingham criteria can rule out the presence of HF whereas the presence of the
criteria should be used in combination with radiographic evidence, such as an echocardiography,
to confirm the diagnosis. The Framingham criteria are listed in Table 1 below. A definite
diagnosis requires a minimum of two major, or one major and two minor criteria present
concurrently. Additionally, minor criteria cannot be attributable to any other condition.

Table 1. Framingham Clinical Diagnostic Criteria for Congestive Heart Failure
Major Criteria

Minor Criteria

Paroxysmal nocturnal dyspnea or orthopnea

Ankle edema

Neck-vein distention

Night cough

Rales

Dyspnea on exertion

Cardiomegaly

Hepatomegaly

Acute pulmonary edema

Pleural effusion

S3 gallop

Vital capacity decrease 1/3 from maximum

Increased venous pressure ≥ 16 cm of water

Tachycardia (rate of ≥ 120 bpm)

Circulation time ≥ 25 seconds
Hepatojugular reflux
Major or Minor Criterion
Weight loss ≥ 4.5 kg in 5 days in response to treatment*
*Serves as a major criterion if it occurred during therapeutic intervention for CHF; if due to
other factors it is a minor criterion.
Note. Adapted from “The Natural History of Congestive Heart Failure: the Framingham
Study” by McKee et al. New England Journal of Medicine. 1971;285(26), 1441-1446.
Diagnosis by HFrEF and HFpEF is complicated by the heterogeneity of the disease
processes and can be particularly difficult for HFpEF (2, 5). Maestre et al. (22) cross-matched
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HF confirmed by echocardiographic diagnostic criteria of LV dysfunction with the results
obtained using the Framingham clinical diagnostic criteria for HF to see how the latter performed
in ruling out SHF (EF < 45%) and DHF (EF > 45%). The analysis revealed that the Framingham
criteria can conclusively rule out the presence of SHF but not DHF (likelihood ratio for negative
test result 0.04 vs. 0.10, respectively). Other than in isolated events, systolic and diastolic LV
dysfunction alone cannot accurately distinguish between HF subtypes as many individuals
display characteristics of both (2, 5, 13). However, when categorized by LVEF, distinct
differences in etiology, risk profiles, and response to treatment are revealed (23). Additionally,
most clinical trials and guidelines have customarily used LVEF for categorizing HFrEF and
HFpEF though some might argue it is not the optimal parameter for evaluating LV systolic
function (24, 25).
Various EF cutpoints have been used to define HFrEF and HFpEF however, the 2013
ACCF/AHA guidelines (2) for HF management defines HFrEF by an EF   and FpEF by
an EF ≥ 50%. Additionally, a third subtype that is often excluded altogether or grouped
into one of the other two classes also exists. This subclass is considered heart failure with
mid-range ejection fraction (HFmrEF) and it is classified as an EF ranging from 41% to
49%. Participants with HFmrEF have been reported to most likely have primarily mild
systolic dysfunction but also have features of diastolic dysfunction (5). Aside from
classifying EF, the ACCF/AHA Guidelines (2) also reported several criteria that have been
proposed to define HFpEF including:
1) Clinical signs or symptoms of HF
2) Evidence of preserved or normal LVEF
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3) Evidence of abnormal left ventricular diastolic dysfunction (LVDD) that can be
determined by Doppler echocardiography or cardiac catheterization

However, these proposed criteria were adapted from a 2000 study (26) in which Vasan et al.
underscored the importance of distinguishing between the HF subtypes and called for the
development of uniform criteria to diagnose HFpEF. Other than the brief mention of these
proposed criteria, the guideline itself did not recommend any specific diagnostic criteria for
HFpEF. In place, large epidemiological studies looking to define HFpEF have instead adapted
previous definitions to include a LVEF cut point. Some of these key studies have been included
in Table 2 below.
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Table 2. Definitions of HFpEF Used in Epidemiological Studies of HFpEF
Study
Cohort Year
LVEF
HFpEF Diagnosis
Helsinki 1997 FS ≥ 0.25 At least 3 of the following (1) history of breathlessness on
Kupari (27)
Ageing
ordinary effort; (2) audible ventricular gallop sound or HR
Study
90 bpm at rest; (3) pulmonary venous congestion on CXR
(consensus of 2 observers) or abnormal neck vein distention
or palpable hepatomegaly; and (4) cardiothoracic ratio >
0.55 on CVR.
FS from protocol echocardiogram at study visit
Olmsted 1998
≥ 50%
Modified Framingham criteria.
Senni (28)
County
LVEF from abstraction of medical record from within 3 wk
of HF diagnosis.
FHS
1999
≥ 50%
Framingham criteria
Vasan (29)
LVEF from protocol echocardiogram at FHS study visit
SHS
2000
> 54%
Modified Framingham criteria
Devereux (30)
LVEF from protocol echocardiogram at SHS study visit
CHS
2001
Qualitative
Expert panel adjudication based on review of pertinent data
Kitzman (31)
as normal; on hospitalization or outpatient visits for CHF, including
history, physical examination, chest x-ray reports, and
medication administration. Self-report of a physician
diagnosis of CHF was confirmed by medical record
documentation.
Gottdiener
CHS
2002
Qualitative assessment of systolic function from protocol
echocardiogram at CHD study visit
(32)
Olmsted
2006
≥
50%
Framingham criteria
Bursi (33)
County
Prospective study-specific echocardiogram
ICD/DRG discharge codes (validated against Framingham
criteria in a subset)
LVEF from clinical echocardiogram performed within 30
days of HF hospitalization
EFFECT
2006
>
50%
Framingham criteria
Bhatia (35)
study
LVEF abstracted from HF hospitalization
FHS
2011
> 45%
Framingham criteria
Lam (36, 37)
LVEF assessed within 1 y of hospitalization (without
intervening event)
Olmsted 2015
> 50%
ICD codes from hospital discharges or outpatient visits
Gerber (38)
County
(validated against Framingham criteria in a subset);
LVEF assessed at Mayo clinical by echocardiography w/in
90 days of HF diagnosis
CHF indicates chronic heart failure; CHS, Cardiovascular Health Study; CXR, chest X-ray; DRG, diagnosisrelated group; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; FHS, Framingham Heart Study;
FS, fractional shorting; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, hazards
ratio; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; and SHS, Strong
Heart Study.
Note. Adapted from, “Heart Failure with Preserved Ejection Fraction in Perspective” by Pfeffer et al.
Circulation research. 2019;124(11), 1598-1617.
Owan (34)

Mayo
Clinic

2006

≥ 50%
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PATHOPHYSIOLOGY
An estimated 17 primary etiologies of HF exist and over two-thirds can be attributed to
just four underlying conditions: ischemic heart disease, chronic obstructive pulmonary disease,
hypertensive heart disease, and rheumatic heart disease (39). In many cases the exact etiology of
HF is unknown or related to a combination of different etiologies. Regardless, HF often
manifests secondary to structural and/or functional abnormalities of the myocardium which most
often result in systolic and/or diastolic dysfunction (5, 6). However, HF can also result from
abnormalities of the pericardium, myocardium, endocardium, heart rhythm, or conduction.
Cardiac remodeling describes a progressive series of changes in the shape, size, and
function of the heart (40). It is one of the most important pathophysiological processes in the
development and progression of HF (41). Cardiac remodeling is often initiated by damage to the
myocardium or increases in wall stress and is characterized by changes in the cardiomyocytes
themselves and in the makeup of the extracellular matrix (ECM) (40). The ECM is important for
maintaining the structural and functional integrity of the heart, predominately via collagen fibrils.
Molecules involved in the composition or activity of the extracellular matrix that are released
into circulation can be measured to detect remodeling. For example, serum concentrations of
collagen fragments are positively correlated with remodeling and the development of fibrosis in
the heart.
Heart failure is often considered a disease of the elderly, particularly in HFpEF (42–44).
Left ventricular wall stress can occur in response to age-related modifications of the
cardiovascular system such as increased afterload, diminished chronotropic and inotropic
responses, increased intracardiac pressures with ventricular filling, and impaired vasodilation
(45, 46). Cardiac remodeling response to stress can result in hypertrophy of the cardiomyocytes
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(47). Hypertrophied cardiomyocytes demand more oxygen and energy, and failure to meet these
needs can result in a hypoxic environment in which excess free radicals are produced (48).
Interestingly, deficits in myocardial oxygen use in HFpEF has been correlated with
hemodynamic severity (3), however, the cellular mechanisms in HFpEF specifically remain
unclear (1). In response, cardiomyocytes release pro-inflammatory cytokines and chemokines in
order to attract macrophages to the area (49). Macrophages are rich in matrix metalloproteinases
(MMPs) which are key regulators in ECM turnover (50). Although tissue inhibitors of
metalloproteinases (TIMPs) are responsible for inhibition of these proteins, with aging, levels of
some TIMPs and MMPs isoforms are increased and correlate with variables of diastolic
dysfunction (51). The isoform MMP-9, can process several cytokines including IL-6 and TNF-α
and is strongly associated with increased LV stiffness and end diastolic dimension in the aging
heart (50).
This describes one probable pathophysiological explanation behind cardiac remodeling
and the development of HF overall in the aging heart. Although several other etiologies and
resultant compensatory mechanisms exist, elucidating this disease process in older populations is
important given the significant increase in prevalence and incidence in the elderly (44). Other
than LV hypertrophy and stiffness, other potential compensatory mechanisms include increased
cardiac output via the Frank-Starling mechanism and increased mean arterial pressure via
neurohormonal systems (4).
HFrEF
As previously reported, left ventricular cardiac remodeling is one of the most important
pathophysiological processes in HF (41). Four patterns of LV remodeling that have been
identified include normal geometry, concentric remodeling, concentric hypertrophy and eccentric
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hypertrophy. In HFrEF, eccentric hypertrophy is the most common type of LV remodeling,
however, a subset of those with HFrEF have concentric hypertrophy. The classic history of
HFrEF begins with the initial damage to the myocardium, which initiates compensatory
mechanisms including LV hypertrophy. Neurohormonal activation is also increased in attempt to
stabilize cardiac output and contractility leading to further LV systolic dysfunction.
In a large multinational longitudinal study, Nauta et al. (41) examined differences in the
pathophysiology, clinical characteristics, and response to treatment in HFrEF patients according
to LV geometry. To the surprise of the investigators, a sizable portion of those with HFrEF
exhibited reduced LVEF with concentric remodeling rather than eccentric remodeling.
Additionally, many of those with HFrEF and concentric hypertrophy had a profile similar to
HFpEF patients as they were predominately older, hypertensive women. In a sub-analysis, the
investigators examined the biomarker profiles according to LV remodeling in which HFrEF
patients with concentric hypertrophy were characterized by markers of oxidative stress and
inflammation.
HFpEF
Patients with HFpEF comprise about half of all patients with HF (27, 29, 31, 33, 52), yet
they frequency experience delayed diagnosis and have limited treatment options (5, 53). These
patients are more likely to be elderly women with small, hypertrophied ventricles (43, 54) and
several cardiovascular and non-cardiovascular comorbidities including obesity, hypertension,
coronary artery disease, and metabolic syndrome (1, 54). The high prevalence of comorbid
conditions in HFpEF may explain the cardiac changes observed in this subtype (1).
Conversely, HFpEF is characterized by the presence of left ventricular diastolic
dysfunction (LVDD) (55). Evidence of LVDD is considered a preclinical condition defined as
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the inability of the LV to fill to an adequate end-diastolic volume at an acceptable pressure (56).
Kane et al. (13) reported about one in four adults with moderate-severe diastolic dysfunction
may develop HF. Although LVDD can occur in HFrEF just as LV systolic dysfunction can occur
in HFpEF, LVDD has been reported to be the primary mechanism in HFpEF and the cause of the
most unifying hemodynamic finding in HFpEF, elevated LV filling pressures (1, 55).
Furthermore, diastolic dysfunction has been shown to be an independent and common predictor
of HFpEF and can help strengthen the diagnosis in the presence of other criteria including signs
and symptoms of HF which are often nonspecific (54).
Despite the strong associations with LVDD in HFpEF it is important to also consider
these patients may exhibit several other abnormalities including, but not limited to, LV systolic
dysfunction, left atrial dysfunction, or long-standing pulmonary hypertension leading to right
ventricular dysfunction (1, 12). While there has been some success elucidating several organlevel pathophysiological processes in HFpEF, the cellular mechanisms behind many of the
cardiac changes observed in HFpEF are not well understood.
SUMMARY
In summary, HFrEF and HFpEF are two distinct HF subtypes. Left ventricular cardiac
remodeling resulting from injury or stress, including age-related changes, is an important
consideration in the development of HF. Those with HFrEF are typically characterized by
eccentric LV hypertrophy whereas those with HFpEF typically exhibit concentric LV
hypertrophy. Nonetheless, it is important to note that neither eccentric or concentric remodeling
are unique to just HFrEF or HFpEF.
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RISK FACTORS
Traditional HF risk factors are common among the US population. Using data from the
2007-2010 National Health and Nutrition Examination Survey, Kovell et al. (57) estimated onethird of the US adult population has at least one HF risk factor. Common established risk factors
for HF overall include, but are not limited to; older age, male sex, hypertension, obesity, LV
hypertrophy, myocardial infarction, diabetes, smoking, metabolic syndrome, coronary artery
disease, race/ethnicity, and immune activation (2, 21, 23, 43, 56).
Using data from the Framingham Heart Study (FHS) original and offspring cohorts,
Cardiovascular Health Study (CHS), and the Prevention of Renal and Vascular End-stage
Disease study (PREVEND), Ho et al. (23) examined risk factors that were significant for HFrEF
and HFpEF (Table 3). Data from these three longitudinal cohort studies were also used to
examine significant differential effects of clinical covariates on HFpEF versus HFrEF (Table 4).
Male sex was a significant risk factor in HFrEF only whereas age was a significantly stronger
risk factor for HFpEF. Left bundle branch block and previous myocardial infarction were
associated with significantly greater risk in HFrEF compared to HFpEF. Smoking status, LV
hypertrophy, and left bundle branch block were also stronger risk factors in HFrEF than HFpEF.
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Table 3. Final Risk Prediction Models for HFpEF and HFrEF
Risk factors
HFpEF
Age per, 10 years
Male sex
Systolic BP, per 20mmHg
Body mass index, per 4kg/m2

sHR* (95% CI)

P value

1.90 (1.74-2.07)
0.93 (0.78-1.11)
1.14 (1.05-1.24)
1.28 (1.21-1.37)

< 0.0001
0.43
0.003
< 0.0001

Antihypertensive treatment
Previous myocardial infarction

1.42 (1.18-1.71)
1.48 (1.12-1.96)

0.0002
0.006

HFrEF
Age, per 10 years
Male sex
Systolic BP, per 20mmHg
Body mass index, per 4kg/m2
Antihypertensive treatment
Diabetes mellitus

1.66 (1.52-1.80)
1.84 (1.55-2.19)
1.20 (1.10-1.30)
1.19 (1.11-1.28)
1.35 (1.13-1.63)
1.83 (1.48-2.26)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.001
< 0.0001

Current Smoker
Previous myocardial infarction
ECG LV hypertrophy
Left bundle branch block

1.41 (1.14-1.75)
2.60 (2.08-3.25)
2.12 (1.55-2.90)
3.17 (2.11-4.78)

0.0015
< 0.0001
< 0.0001
< 0.0001

BP, blood pressure; CI, confidence interval; HF, heart failure; HFpEF, HF
with preserved ejection fraction; HFrEF, HF with reduced ejection fraction;
LV, left ventricular; ECG; electrocardiogram; sHR, subdistribution hazard
ratio.
*Hazard ratio is expressed per increase in continuous variables as specified
in the table and for presence vs absence of dichotomous variables.
Note. Adapted from, “Predicting Heart Failure with Preserved and Reduced
Ejection Fraction: The International Collaboration on Heart Failure
Subtypes” by Ho et al. 2016. Circulation: Heart Failure, 9(6), e003116.
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Table 4. Differential Effects of Risk Factors on HFpEF vs HFrEF
HFpEF
HFrEF
p for
sHR* (95% CI)
sHR* (95% CI)
equality
Age, per 10 years
1.91 (1.78–2.06) 1.69 (1.59–1.81)
0.02
Male sex
0.91 (0.79–1.05) 1.87 (1.63–2.16)
< 0.0001
Systolic BP, per 20mmHg
1.13 (1.05–1.21) 1.20 (1.12–1.28)
0.24
Body mass index, per 4 kg/m2
1.28 (1.22–1.36) 1.18 (1.11–1.25)
0.05
Antihypertensive treatment
1.41 (1.21–1.65) 1.33 (1.14–1.54)
0.59
Diabetes mellitus
1.42 (1.17–1.72) 1.58 (1.32–1.90)
0.44
Current Smoker
1.04 (0.85–1.28) 1.44 (1.21–1.72)
0.02
Previous myocardial infarction
1.30 (1.02–1.67) 2.70 (2.25–3.24)
< 0.0001
ECG LV hypertrophy
1.16 (0.84–1.60) 2.08 (1.60–2.69)
0.009
Left bundle branch block
1.30 (0.81–2.09) 3.65 (2.62–5.09)
0.0008
*Hazard ratio is for the presence versus absence of dichotomous predictors, and per
increase in continuous predictors as specified in the table with all covariates shown in the
model simultaneously. BP indicates blood pressure; CI, confidence interval; HF, heart
failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection
fraction; and sHR, subdistribution hazard ratio.
Note. Adapted from, “Predicting Heart Failure with Preserved and Reduced Ejection
Fraction: the International Collaboration on Heart Failure Subtypes” by Ho et al. 2016.
Circ Heart Fail, 9(6), e003116.

Many of the original large longitudinal cohort studies in HF have historically included
almost exclusively white participants including the FHS (100% whites), PREVEND (96%
whites), and CHS (85% whites) (23). More recent investigations that have examined HF risk
across different race/ethnicities have revealed significant risk differences (44, 58, 59). Therefore,
it is important to include a brief synopsis of some of the investigations that have examined HF in
more diverse samples.
The Health, Age, and Body Composition, or Health ABC Study, examined the
epidemiology of incident HF by race and gender in an elderly cohort of 2934 participants (58.6%
white, 41.4% black) without HF at baseline. The median follow-up time was 7.1 years in which
8.8% of the population developed HF. They found that men and blacks were more likely to
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develop HF, however, there were not statistically significant sex-based differences observed.
Blacks had a higher overall proportion of HF attributable to modifiable risk factors compared to
whites (67.8% vs. 48.9%) with a > 5% higher population attributable risk in 6 of 8 risk factors
assessed (coronary heart disease, uncontrolled blood pressure, LV hypertrophy, reduced
glomerular filtration rate, smoking, and increased heart rate). Differences in survival rates after
HF were not statistically significant, however, rehospitalization rates were significantly higher in
blacks.
Bahrami et al. (58) examined differences in incident CHF in 6814 men and women (4584 years of age) who participated in the Multi-Ethnic Study of Atherosclerosis. This cohort
included whites (38.5%), African Americans (27.8%), Hispanics (21.9%) and Chinese
Americans (11.8%) who were free from cardiovascular disease at baseline. Although they did
not stratify by LVEF, it was noted that 63% of the CHF participants had preserved LV function
(LVEF ≥ 40%) After a median follow-up of 4.0 years, 79 participants developed CHF. Cox
proportional hazards models were used to obtain hazard ratios (HRs). African American
participants had the highest incidence rate of CHF, followed by Hispanic, white, and Chinese
Americans. After controlling for age, sex, hypertension, obesity, serum cholesterol level, and
smoking status, analysis revealed African Americans had a significantly greater risk of CHF
compared to whites (Hazard ratio [HR] 2.00; 95% Confidence interval [CI] 1.11-3.61). However,
this relationship was attenuated and no longer statistically significant after controlling for
baseline LVEF determined by magnetic resonance imaging. There was not a significant
association seen in the other race/ethnicities.
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HEART FAILURE AND INFLAMMATION
In 2001, the National Institutes of Health’s Biomarkers Definitions Working Group defined
biological markers, or biomarkers, as, “a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention” (60). Biomarkers can be used to help diagnose an
abnormal condition, to stage the extent of a disease, to indicate disease prognosis, or to
determine response to intervention.
In a 2012 review, van Kimmenade et al. (61), examined the emerging roll of biomarkers in
HF after the clinical introduction of testing B-type natriuretic peptide (BNP) and N-terminal
proBNP (NT-proBNP) in the early 2000’s. Combining recommendations from various
investigators and organizations, van Kimmenade et al. defined four conditions that should be met
in order for the investigation of a biomarker to be useful. These conditions are as follows:
1) The methods by which a novel biomarker is judged (compared to or in combination with
other biomarkers) should be thorough and evaluated across a wide range of patients that
are typical of the diagnosis for which the biomarker will be applied. Additionally, the
statistical methods used to evaluate the biomarker should be contemporary, rigorous,
standardized and fair.
2) Measurement of a novel HF biomarker should be easily achieved within a short period of
time and provide acceptable accuracy, and assays for its measurement should have
defined biological variation and low analytical imprecision.
3) The biomarker should primarily reflect important (patho)physiological process(es)
involved in HF presence and progression; use of a biomarker that is reflective of heart
disease but originates outside of the myocardium is acceptable as long as such a
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biomarker provides independently useful information involved in the diagnosis,
prognosis, progression, or therapy of HF syndromes.
4) The biomarker must provide clinically useful information for caregivers (physicians,
nurses, and others) and patients to facilitate more swift and reliable
establishment/rejection of a diagnosis and more accurate estimation of prognosis and to
inform more successful therapeutic strategies. The information from such a biomarker
should not recapitulate clinical information already available at bedside and must be
additional to information provided by other biomarkers.

According to the authors, although many are close, BNP and NT-proBNP are the only
biomarkers thus far that have met the above criteria. This is consistent with the 2017 Focused
Update (62) of the ACCF/AHA guidelines, which recommend measuring natriuretic peptide
biomarkers for the prevention, diagnosis and prognosis of HF. In addition to BNP and NTproBNP, the 2013 ACCF/AHA guidelines recommended using cardiac troponin T or I,
biomarkers of myocardial injury, for evaluating HF prognosis but not for predicting new onset
HF. Although other common cardiovascular biomarkers have been implicated in HF, current
evidence is not enough to make these recommendations. Furthermore, considering the
difficulties diagnosing HF, particularly in HFpEF, a multi-marker strategy may be useful in
establishing risk and diagnosing HF in combination with other diagnostic criteria.
So far, the natriuretic peptides, specifically BNP, have been shown to have the best
predictive value in HF compared to other biomarkers (40). Although BNP is not without some
limitations, one being that it can be associated with a variety of cardiac and noncardiac causes
(2). Furthermore, the predictive value of BNP in HFpEF is not as well established as in HFrEF or
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HF overall. A 2012 analysis (63) examined BNP values in 159 HFpEF (EF > 50%) patients and
found that about one-third had BNP levels below typical diagnostic thresholds. Gladden et al.
(54) attributed the lower BNP values observed in HFpEF to obesity, elevated filling pressures in
the early disease process, and lower wall stress secondary to concentric remodeling (64).
However, other reports have distinguished that while BNP values in HFpEF are lower than in
HFrEF, they are still elevated (40). According to an AHA Scientific Statement (40), there is a
need for appropriate biomarkers that can properly diagnose HFpEF and provide
pathophysiologically relevant classification. Since HF represents a complex, heterogeneous
syndrome, biomarkers in HF are most commonly classified by the disease process they are
involved in (61) . Candidate biomarkers involved in inflammation in HF include CRP, TNF-α,
sTNF-R1, and IL-6. Additionally, IL-6 can also be classified under the extracellular-matrix
remodeling disease process.
A prospective analysis from the Health ABC study (65), examined the associations
between CRP, IL-6 and TNF-α and incident HF overall, HFrEF, and HFpEF. The sample
included 2610 older adults without HF at baseline. Following adjustment for baseline
characteristics and medication, IL-6, TNF-α, and CRP were significant predictors of incident HF
overall in individuals without baseline atherosclerotic disease (n = 1945) (Hazard ratio [HR]
1.40; 95% Confidence interval [CI] 1.18-1.66; p < 0.001, HR 1.40; 95% CI 1.06-1.84; p = 0.018,
and HR 1.19; 95% CI 1.05-1.36; p = 0.009, respectively). In those with atherosclerotic disease at
baseline (n = 665), including coronary heart disease, cerebrovascular disease, or peripheral artery
disease, IL-6 and TNF-α were significant predictors of HF risk (HR 1.23; 95% CI 1.02-1.48; p =
0.032, and HR 1.73; 95% CI 1.26-2.38; p = 0.001, respectively), however, CRP was not. This
relationship was also examined by HFrEF (EF ≤ 45%) and HFpEF (EF > 45%). In HFrEF, risk
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associated with elevated IL-6 was borderline significant (HR 1.21; 95% CI 0.99-1.48; p = 0.067)
whereas TNF-α and CRP were not significant. In HFpEF, IL-6 and TNF-α were strongly
associated with risk (HR 1.49; 95% CI 1.19-1.86; p < 0.001, and HR 1.81; 95% CI 1.23-2.68, p =
0.003, respectively) however, CRP was not. The weak association with CRP in this study is
contradicting to other studies that have reported CRP as strong independent predictor of HF (66–
69). The authors attributed this finding to the rigorous controlling for confounders in their study.
In some studies, the predictive value of CRP was attenuated in patients with other traditional
cardiovascular risk factors present (70–72) however, this phenomenon does not seem to
represent the majority.
Bozkurt et al. (73) examined the emerging role of proinflammatory cytokines, CRP, and
erythrocyte sedimentation rate in patients with HF. Table 5 includes a number of investigations
that have reported concentrations of various cytokine and cytokine receptors in HF. Out of all of
the cytokines and cytokine receptors, TNF-α appears to be the most well-studied with a majority
of studies reporting elevated concentrations in HF patients. According to the table, the second
most well investigated cytokine is IL-6, which is also elevated in a majority of the studies. It is
also evident that although fewer studies have investigated concentrations of sTNF-R1 in HF,
those that have all demonstrate these concentrations are also elevated. Additionally, Table 6
shows CRP concentrations are also elevated in HF patients.
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Table 5. Peripheral Levels of Cytokines and Cytokine Receptors in Heart Failure

nd: Not done, +: levels elevated, -: levels not elevated
TNF-α, Tumor necrosis factor alpha, IL-1 Interleukin-1, IL-2 Interleukin-2, IL-6 Interleukin-6, IFN-c
interferon gamma, sTNFR1 soluble TNF receptor R1, sTNFR2 soluble TNF receptor R2, IL-1RA IL-1
receptor antagonist, IL-6R IL-6 receptor, sST2 soluble ST2-member of IL-1 receptor family

Adapted from, “Biomarkers of inflammation in heart failure.” by Bozkurt et al. 2010. Heart
failure reviews, 15(4), 331-341.
Table 6 demonstrates the associations of various biomarkers in HF and the strength of
these associations (73). Concentrations of TNF-α, IL-6, sTNF-R1, and CRP are shown to
correlate with disease severity, prognosis and HF outcomes. Additionally, three of these four
biomarkers with available data (TNF-α, IL-6, and CRP) also demonstrate predictive value in the
development of HF in asymptomatic patients. There was no data for this association in sTNF-R1.
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Table 6. Role of Inflammatory Biomarkers in Heart Failure

TNF-a Tumor necrosis factor alpha, IL-6 Interleukin-6, IL-18 Interleukin-18, sTNFR1 soluble TNF
receptor R1, sTNFR2 soluble TNF receptor R2, IL-1RA IL-1 receptor antagonist, sST2 soluble ST2member of IL-1 receptor family, IL-10 Interleukin-10, MCP-1 Monocyte chemoattractant protein-1,
CRP C-reactive protein, ESR erythrocyte sedimentation rate, HF heart failure, n/d no data available
+++ Supported by large number of studies and more than one large-scale clinical trial
++ supported by several number of studies and/or small-scale clinical trials and/or one large-scale
clinical trial
+ supported by one small study or one small clinical trial
a One study suggested that elevated levels were associated with increased mortality [76], whereas the
other study suggested that elevated levels were associated with better prognosis [79]
Adapted from, “Biomarkers of inflammation in heart failure.” by Bozkurt et al. 2010. Heart failure
reviews, 15(4), 331-341.

SUMMARY
In summary, the evidence suggests various cytokines, cytokine receptors, and biomarkers
of inflammation are elevated in HF patients and positively associated with HF risk. Currently,
there is insufficient evidence supporting the use of these biomarkers in the diagnosis and
prognosis of HF. Considering the challenges that are associated with diagnosing HF, there is an
emerging need to determine the efficacy of using common biomarkers of other disease processes
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in HF. It is likely that a combination of biomarkers may provide the greatest risk stratification
rather than one single biomarker. Additionally, given the distinct differences in etiology and risk
factors of HFrEF and HFpEF, there is also a need to investigate this relationship by HF subtype.
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Chapter Three: Methodology
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The purpose of this prospective study was to examine the associations between elevated
high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and soluble tumor necrosis
factor- receptor-1 (sTNF-R1) and the risk of heart failure with reduced ejection fraction
(HFrEF) and heart failure with preserved ejection fraction (HFrEF). This section provides the
details of the methodology used to address the research question.

DATA COLLECTION
The Multi-Ethnic Study of Atherosclerosis (MESA) is an ongoing prospective study funded
by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The
primary objectives of the MESA are to determine the characteristics related to the progression of
subclinical cardiovascular disease (CVD) and also from subclinical to clinical CVD. Details on
the MESA have been published elsewhere (1). In brief, the sample included 6,814 men and
women (45-84 years of age) who were free from clinical cardiovascular disease at baseline.
Participants identified as Caucasian (38%), African American (928%), Hispanic (22%), or
Chinese American (12%) and were recruited from six university-affiliated field centers in the
United States:
1) University of California, Los Angeles, CA
2) University of Minnesota, St. Paul, MN
3) Northwestern University, Chicago, IL
4) Wake Forest University, Winston-Salem, NC
5) John Hopkins University, Baltimore, MD
6) Columbia University, New York, NY
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Since the MESA is concerned with the natural history of subclinical and clinical CVD,
participants with any known clinical disease were excluded from the sample. Additionally,
participants with any incompatibility with the long-term design of the study or other components
of the MESA exam were also excluded. Eligibility status was determined based off self-reported
information.
The exclusion criteria were:
1. Age younger than 45 or older than 84 years
2. Physician-diagnosed:
a. Heart attack
b. Angina or taking nitroglycerin
c. Stroke or TIA
d. Heart failure
3. Current atrial fibrillation
4. Having undergone procedures related to CVD
5. Active treatment for cancer
6. Pregnancy
7. Any serious medical condition which would prevent long-term participation
8. Weight > 300 pounds
9. Cognitive inability as judged by the interviewer
10. Living in a nursing home or on the waiting list for a nursing home
11. Plans to leave the community within five years
12. Language barrier (speaks other than English, Spanish, Cantonese or Mandarin)
13. Chest CT scan in the past year
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The baseline exam took place from July 2000-2002 and an additional four exams have been
completed since 2012. Since Exam 1, participants have been contacted every 9-12 months to
determine if any events of interest had occurred.

The current study was reviewed and approved by the Institutional Review Board of the
University of North Florida (Appendix A). Data from the MESA was requested and obtained
from the National Institutes of Health/National Heart, Lung, and Blood Institute: Biologic
Specimen and Data Repository Information Coordinating Center (2).

PRIMARY DEPENDENT VARIABLE
The primary dependent variable was time to congestive heart failure (TTCHF). The
variable name in the MESA is congestive heart failure (CHF) but this will be referred to as “HF”
instead as it is the preferred terminology. Heart failure was an adjudicated event classified as
either definite, probable, or absent. Potential HF events were primarily identified by postbaseline follow-up calls but other means of identifying events included participant notification,
MESA clinic visits, National Death Index, and public obituaries. Medical records were obtained
and reviewed by a panel of physicians to determine if the event met MESA criteria. Probable HF
required evidence of HF symptoms, physician diagnosis of HF, and patient receiving medical
treatment for HF. Definite HF required one or more additional criteria:
1) Pulmonary edema/congestion by chest x-ray
2) Dilated ventricle or poor left ventricular function by echocardiography or
ventriculography
3) Evidence of left ventricular diastolic dysfunction
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Participants who did not meet any criteria or with just a physician diagnosis of HF without any
other evidence were considered to not have HF. If the medical report specified a specific ejection
fraction (EF), the measured value was recorded. For reports that specified EF value as a range,
the midpoint value rounded down to the nearest whole number was recorded. For some reports,
EF was classified as either ‘low’ or ‘normal.’ Both ‘probable’ and ‘definite’ HF events were
included in this analysis. Additionally, for the subtype analysis, those with an EF < 50% or
classified as “low” at the time of diagnosis were considered HFrEF and those with an EF ≥ 50%
or classified as “normal” were considered HFpEF.

PRIMARY INDEPENDENT VARIABLES
The primary independent variables in the study included hs-CRP, IL-6, and sTNF-R1.
Baseline serum samples were drawn after at least 12 hours of fasting, processed 15-30 minutes
following venipuncture, and stored at either the University of Vermont or the University of
Minnesota (3). All biomarkers were analyzed in the Laboratory for Clinical Biochemistry
Research at the University of Vermont (Burlington, VT).
High-sensitivity C-reactive protein was measured using the BNII nephelometer (N High
Sensitivity CRP; Dade Behring Inc., Deerfield, IL). This instrument utilizes a particle enhanced
immunonephelometric assay to determine hs-CRP concentration. The assay range is 0.1751100mg/L. Concentrations > 10 mg/L were excluded as this is more indicative of acute infection
or trauma (4). The hs-CRP variable was then dichotomized as either elevated (> 3-10 mg/L) or
normal (≤ 3 mg/L). This range of hs-CRP concentration is classified as high risk according to
the 2003 statement for healthcare professionals from the Centers for Disease Control and
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Prevention and the American Heart Association (4). Following dichotomization, the variable
was log-transformed.
Interleukin-6 concentration was measured by ultra-sensitive ELISA (Quantikine HS
Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN). The lower detection limit was <
0.095 pg/mL with a detection range of 0.156-10.0 pg/mL. Participants were grouped by gender
and 10-year age bands for categorization. The calculated outliers for each age and gender group
were excluded and the remaining values were log-transformed. The 75th percentile of the logtransformed variable for each group was considered elevated and values below the 75 th percentile
were considered normal. All elevated groups were combined into one and all non-elevated
groups were also combined resulting in a single dichotomized variable specific for age and
gender.
The sTNF-R1 variable was measured by ultra-sensitive ELISA (Quantikine HS Human
sTNF R1 Immunoassay; R&D Systems, Minneapolis, MN). The lower detection level was 1-3
pg/mL with a detection range of 7.8-500 pg/mL. The variable was then dichotomized using the
same methods as previously described in IL-6. Participants were grouped by gender and 10-year
age bands for categorization. The calculated outliers for each age and gender group were
excluded and the remaining values were log-transformed. The 75th percentile of the logtransformed variable for each group was considered elevated and values below the 75 th percentile
were considered normal. All elevated groups were combined into one and all non-elevated
groups were also combined resulting in a single dichotomized variable specific for age and
gender.
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OTHER INDEPENDENT VARIABLES
The potential confounding variables that were controlled for in this study were all
measured at Exam 1, the baseline exam, and they included the following:
AGE
Age was self-reported on the personal history form. This was included in the analysis as a
continuous variable. Additionally, age was categorized in bands of 10 for the descriptive results
to demonstrate the age distribution by heart failure status in the sample.
SEX
Sex was self-reported on the personal history form as either male or female.
RACE/ETHNICITY
Race was self-reported as either Caucasian, African American, Hispanic, or Chinese.
SMOKING
Smoking status was self-reported on the personal history form and was a created variable
categorized as “Current, Former, or Never.” Those who answered “yes” to the question, “Have
you smoked cigarettes in the past 30 days?” were considered current smokers. Those who
answered “no” to having smoked cigarettes in the past 30 days but “yes” to the question, “Have
you smoked at least 100 cigarettes in your lifetime?” were considered former smokers. Those
who answered “no” to having smoked at least 100 cigarettes in their lifetime were considered
never smokers.
PHYSICAL ACTIVITY
Physical activity (PA) was self-reported on the PA form. This was also a created variable,
rather than a variable that is directly obtained as part of the MESA exam. Total intentional
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exercise was assessed based off the self-reported number of days per week and hours/minutes per
day spent participating in the following activities:
1) Walking for exercise, pleasure, social reasons, walking during work breaks, or walking
the dog is classified as intentional walking
2) Dancing in church, ceremonies, or for pleasure
3) Team sports such as softball, volleyball, basketball or soccer
4) Dual sports such as tennis, racketball, or paddleball
5) Individual activities such as golf, bowling, yoga, or T’ai Chi
6) Moderate effort conditioning activities such as low impact aerobics, recreational (slow)
bicycling, rowing on a rowing machine or in a lake, swimming in a pool or lake, or using
weight-lifting or conditioning machines at a health club.
7) Heavy effort conditioning activities such as high impact aerobics (e.g., Tai-bo, kick
boxing, judo, karate), competitive or maximum effort running, bicycling, swimming, and
work on health club machines.
A continuous MET·min/wk variable was calculate based off participant responses. A
dichotomized PA variable was then created according to the 2018 Department of Health and
Human Services Physical Activity Guidelines for Americans (5). Those who reported ≥ 500
MET·min/wk were considered sufficiently active and those < 500 MET·min/wk were considered
insufficiently active.
WAIST CIRCUMFERENCE
Waist circumference measurements ≥ 102 cm or ≥ 88 cm for men and women, respectively,
were considered at risk (6).
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BLOOD PRESSURE
The last two of three blood pressure (BP) measurements were averaged for both systolic
blood pressure (SBP) and diastolic blood pressure (DBP). These variables were then categorized
according to the most recent blood pressure recommendations (7) as: normal SBP < 120 mmHg
and DBP < 80 mmHg: elevated SBP 120-129 mmHg and DBP < 80 mmHg: or hypertensive SBP
≥ 130 mmHg or ≥ 80 mmHg. Additionally, participants taking any anti-hypertensive medications
were classified as hypertensive as well.
LOW-DENSITY LIPOPROTEIN CHOLESTEROL
The low-density lipoprotein cholesterol (LDL-C) variable was a created variable in the
MESA and was categorized according to the National Cholesterol Education Program Guidelines
(NCEP) (8). Using these categorizations, LDL-C was dichotomized as < 130 mg/dL or ≥ 130
mg/dL. Additionally, lipid-lowering medication use was self-reported on the medications form
and confirmed during the medication interview. Participants taking lipid-lowering medications
were also classified as having elevated LDL-C.
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
The continuous high-density lipoprotein cholesterol (HDL-C) variable was used to create
a gender-stratified dichotomous variable according to the 2001 NCEP Guidelines (8), in which
concentrations < 40 mg/dL for females or < 50 mg/dL for males were considered low.
Additionally, participants taking lipid-lowering medications were also classified as having low
HDL-C.
TRIGLYCERIDES
Triglycerides were categorized in the MESA according to the 2001 NCEP Guidelines (8).
Using these categorizations, triglyceride levels were dichotomized as < 150 mg/dL or ≥ 150
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mg/dL. Additionally, participants taking lipid-lowering medications were also classified as
having elevated triglycerides.
FAMILY HISTORY OF MYOCARDIAL INFARCTION
Family history of myocardial infarction was a created variable dichotomized (Y/N) by the
self-reported history of myocardial infarction in a parents, siblings, or children.
STATINS
Statin use was reported on the medications form and confirmed during the medication
interview. Using this information, the MESA created a dichotomized (Y/N) statin use variable.
ORAL STEROIDS
Oral steroid use was reported on the medications form and confirmed during the
medication interview. Using this information, the MESA created a dichotomized (Y/N) oral
steroid use variable.
ASPIRIN
Aspirin use was reported on the medications form and confirmed during the medication
interview. Using this information, the MESA created a dichotomized (Y/N) aspirin use variable.
NSAIDS (EXCLUDING ASPIRIN)
Use of NSAIDS, excluding aspirin, was reported on the medications form and confirmed
during the medication interview. Using this information, the MESA created a dichotomized
(Y/N) NSAID use variable.

STATISTICAL ANALYSIS
Statistical Analysis Software 9.4 (9) was used for data management in which complex
variable recodes, coding verification, and statistical analyses were performed. Descriptive
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characteristics were obtained using the means (PROC MEANS) and frequency (PROC FREQ)
procedures for continuous and categorical variables, respectively. The univariate procedure
(PROC UNIVARIATE) was used to calculate outliers and to determine the 75 th percentile of IL6 and sTNF-R1. SAS was also used to log-transform hs-CRP, IL-6 and sTNF-R1 to make the
distributions normal or near normal.
Separate proportional hazards regression procedures (PROC PHREG) were used to
calculate multivariable adjusted hazard ratios (HR) to determine risk of HF overall, HFrEF and
HFpEF according to baseline hs-CRP, IL-6 and sTNF-R1 concentrations. Participants without
the necessary EF data were excluded from the subtype analysis. After creating unadjusted and
age-adjusted models, three additional models were made. Model 1 adjusted for demographics
and behavioral covariates including age, gender, race/ethnicity, smoking, and PA. Model 2
adjusted for the variables in Model 1 plus WC, BP, HDL-C, LDL-C, triglycerides, and selfreported family history of MI. Model 3, the fully adjusted model, included Model 2 covariates
plus anti-inflammatory medication use including statins, oral steroids, aspirin, and NSAIDS
(excluding aspirin).
In a separate analysis using proportional hazards regression, covariates included in the
fully adjusted model were chosen using a stepwise backward elimination process. For each
model that was tested, potential covariates that did not contribute significantly based on p = 0.05
were removed and excluded from subsequent analyses. A final parsimonious model was included
to help elucidate the relationship between the independent and dependent variables.

60
REFERENCES
1.

Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis:
objectives and design. Am J Epidemiol. 2002;156(9):871-81.

2.

National Institutes of Health/National Health Lung and Blood Institute: Biologic
Specimen and Data Repository Information Coordinating Center. In: BIOLINCC.
https://biolincc.nhlbi.nih.gov/home/.

3.

MESA Coordinating Center. MESA manual of operations: field center and laboratory
procedures. [cited 2020 Apr 16]. Available from http://www.mesanhlbi.org/publicDocs/MesaMop/MesaMop1-5-01.doc.

4.

Piercy KL, Troiano RP, Ballard, RM, et al. (2018). The physical activity guidelines for
Americans. JAMA, 320(19), 2020-8.

5.

Ford ES, Li C, Zhao G. (2010). Prevalence and correlates of metabolic syndrome based
on a harmonious definition among adults in the US. J Diabetes. 2(3), 180-93.

6.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.
2001;285(19):2486-97.

7.

SAS Institute Inc. 2016. Base SAS® 9.4 Procedures Guide: Statistical Procedures, Sixth
Edition. Cary, NC: SAS Institute Inc.

61

Chapter Four: Manuscript

62

BIOMARKERS OF INFLAMMATION IN HEART FAILURE PATIENTS WITH
REDUCED AND PRESERVED EJECTION FRACTIONS: MULTI-ETHNIC STUDY OF
ATHEROSCLEROSIS
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ABSTRACT
Purpose:

Examine the relationships between high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and soluble tumor necrosis factor-α receptor-1
(sTNF-R1) and the cumulative risk of heart failure with reduced (HFrEF)
and preserved (HFpEF) ejection fractions in a diverse, population-based
sample.

Methods:

Study sample included 6,814 adult (45-84 years of age) men and women
who participated in the Multi-Ethnic Study of Atherosclerosis and were free
of cardiovascular disease at baseline. Cox regression was used to calculate
the hazard ratios (HR) associated with elevated baseline hs-CRP (> 3-10
mg/L), IL-6 (> 75th percentile) and sTNF-R1 (> 75th percentile) and risk of
overall HF, HFrEF (ejection fraction [EF] < 50%), and HFpEF (EF ≥ 50%).

Results:

During ~11.2 years of follow-up there were 178 incident HF diagnoses.
Elevated hs-CRP, IL-6 and sTNF-R1 were associated with a significant
increased risk of HF overall (HR 1.76; 95% Confidence interval [CI] 1.222.52, HR 1.57; 95% 1.07-2.30, and HR 1.91; 95% CI 1.08-3.38,
respectively). Elevated hs-CRP was a significant predictor in both HFrEF
and HFpEF (HR 2.05; 95% CI 1.26-3.35, and HR 1.89; 95% CI 1.09-3.28,
respectively). Baseline IL-6 concentrations were significantly associated
with increased risk of HFrEF in nonsmokers only (HR 2.33; 95% CI 1.045.23) and of HFpEF in African Americans only (HR 5.89; 95% CI 1.5222.80).
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Conclusion:

In a diverse sample of U.S. adults, elevated hs-CRP, IL-6 and sTNF-R1 were
significant predictors of HF. Furthermore, both hs-CRP and IL-6 were
significant predictors in HFrEF and HFpEF.
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INTRODUCTION
Heart failure (HF) is a complex clinical syndrome in which the heart is unable to deliver
the requisite amount of blood to meet metabolic demands or does so only at the cost of increased
filling pressures (1, 2) . The prevalence of HF in the general adult population ranges from 1-3%
(3–6) and increases starkly to over 10% in older populations (6–8). According to estimates from
the 2011-2014 National Health and Nutrition Examination Survey, approximately 6.5 million
Americans are living with HF and this is projected to increase to over 8 million by 2030 (9, 10).
Heart failure most often manifests due to structural or functional abnormalities of the left
ventricle (LV) and resultant systolic or diastolic dysfunction, or a combination of the two (1, 11).
In early investigations, HF was almost exclusively thought to be associated with reduced systolic
function however, repeated observations of HF without systolic dysfunction in the late 20th
century lead to the recognition of HF with diastolic dysfunction (2, 3, 12). These two HF
subtypes were accordingly termed systolic and diastolic HF, though the preferred terminology
today is heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved
ejection fraction (HFpEF). The change in terminology is largely due to the observation that many
HF patients demonstrate some degree of both systolic and diastolic dysfunction (11, 13) but
when classified by left ventricular ejection fraction (LVEF), HFrEF and HFpEF exhibit marked
differences in etiology, risk profiles, and response to treatment (14–18). The need to differentiate
between these distinct subtypes is emphasized by evidence indicating that HFpEF constitutes
~50% of all HF cases (19–23). Furthermore, due to the temporal sequence of discovery, early
drug trials only included those with HFrEF and medications implemented to reduce mortality in
HFrEF have not been shown to be efficacious in HFpEF (3, 11).
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Unfortunately, making this distinction can be difficult because, currently, there is not a
nationally or internationally agreed upon definition, classification system, or gold standard for
the clinical diagnosis of HFpEF (11, 13, 14). Despite this lack of consensus, numerous diagnostic
classifications, produced by various organizations, do exist. The 2013 American College of
Cardiology Foundation (ACCF)/American Heart Association (AHA) Guideline (11) for the
Management of Heart Failure describes the proposed criteria to define HFpEF including; clinical
signs or symptoms of HF, evidence of preserved or normal LVEF, and evidence of abnormal LV
diastolic dysfunction determined by Doppler echocardiography or cardiac catheterization.
Nonetheless, diagnosis of HFpEF remains difficult and primarily a diagnosis of exclusion (24,
25) A 2017 Scientific Statement from the AHA (26) highlighted the need for novel biomarkers to
add meaningful diagnostic information and provide a classification relevant to the
pathophysiology of HFpEF. According the 2017 Focused Update (27) of the aforementioned
ACCF/AHA guidelines, there is only sufficient evidence on the efficacy of a few biomarkers,
namely B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide, cardiac troponin,
and some biomarkers of myocardial fibrosis, to recommend their use in the prevention,
diagnosis, and prognosis of HF. Several other biomarkers in HF have been implicated but there
remains a paucity of data defining their value and the need for further research, including that on
biomarkers of inflammation.
Biomarkers including C-reactive protein (CRP) and pro-inflammatory cytokines
interleukin-6 (IL-6) and tumor necrosis factor- (TNF) have been found to be elevated in those
with HF (28–31) and associated with HF onset (32–35) and prognosis (30, 36–39). One of the
two soluble TNF-α receptors, soluble tumor necrosis factor- receptor-1 (sTNF-R1), is also used
as a marker of TNF-α activity and has been shown to be elevated in HF patients and associated
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with disease severity (40). However, few have investigated the relationship of each of these
biomarkers by HF subtype (29, 37, 41, 42). The aim of this study was to investigate the
association between elevated high-sensitivity CRP (hs-CRP), IL-6, and sTNF-R1 and incident
HFrEF and HFpEF in a diverse sample of U.S. adults who participated in the Multi-Ethnic Study
of Atherosclerosis (MESA).

METHODS
This study analyzed data from the MESA (43), a continuous, multicenter prospective
cohort study sponsored by the National Heart Lung and Blood Institute of the National Institutes
of Health. The primary objectives of the MESA are to 1) determine characteristics related to the
progression of subclinical CVD and 2) to determine the characteristics related to the progression
of subclinical to clinically overt CVD in a diverse, population-based sample. Details on the study
have been published elsewhere (43). In brief, participants were recruited from six regions in the
United States (US) and the final sample included 6,814 Caucasian, African American, Hispanic,
and Chinese men and women (45-84 years of age) who were free of any known CVD at baseline.
The first exam took place over 24 months from 2000-2002 and four additional exams have been
completed since 2012. Participants were contacted for a follow-up interview every 9-12 months
to determine if any new CVD conditions, hospitalizations, treatments, or changes in life habits
had occurred. Additionally, information on any CVD events that occurred during follow-up was
collected from participant interviews, medical records, autopsy reports, death certificates, and, in
the case of out-of-hospital deaths, interviews with or questionnaires administered to physicians,
relatives, or friends. Data from the MESA was requested and obtained from the National
Institutes of Health/National Heart, Lung, and Blood Institute: Biologic Specimen and Data
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Repository Information Coordinating Center (44). The use of MESA data was approved by the
Institutional Review Board of the University of North Florida.
Dependent Variable
The primary dependent variable was time to HF. Heart failure is an adjudicated event in
which interim medical records and deaths records are abstracted and reviewed by at least two
physicians. Eligible HF events are classified as either definite, probable, or absent. Since
asymptomatic disease is not an endpoint of the MESA, HF classification requires the presence of
HF symptoms. In addition to symptoms, classification of probable HF also requires a physician
diagnosis of HF and evidence of the patient receiving medical treatment for HF. Classification of
definite HF requires the same criteria as probable HF and one or more additional criterion such
as pulmonary edema/congestion; dilated ventricle or poor LV function; or evidence of LV
diastolic dysfunction. Participants with a diagnosis of HF but no other evidence are considered to
not have HF. For those with verified HF events, available EF information is obtained and
recorded either by the quantitative value or as ‘Normal’ or ‘Low.’ In the present study, incident
HF overall included those determined to have either probable or definite HF. Participants with an
EF  50% or with an EF classification of ‘Low’ at the time of diagnosis were classified as
HFrEF, and those with an EF  50% or an EF classification of ‘Normal’ were classified as
HFpEF.
Independent Variables
The inflammatory biomarkers of interest included hs-CRP, IL-6 and sTNF-R1. Blood
samples were drawn after at least 12-hours of fasting, processed 15-30 minutes following
venipuncture, and stored at either the University of Vermont or the University of Minnesota (45).
All biomarkers were measured in the Laboratory for Clinical Biochemistry Research at
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University of Vermont (Burlington, VT). High sensitivity CRP was measured using the BNII
nephelometer (N High Sensitivity CRP; Dade Behring Inc., Deerfield, IL). This instrument
utilizes a particle enhanced immunonephelometric assay to determine hs-CRP concentration. The
hs-CRP variable was dichotomized as elevated (> 3-10 mg/L) or normal (< 3 mg/L) (46). Both
IL-6 and sTNF-R1 concentrations were measured using an ultra-sensitive ELISA (Quantikine
HS Human IL-6 Immunoassay and Quantikine Human STNF R1 Immunoassay; R&D Systems,
Minneapolis, MN). For both IL-6 and sTNF-R1, participants were grouped by age bands of 10
(45-55, 56-65, 66-75, > 75) and gender (M/F) and dichotomized at the 75th percentile as either
elevated or normal for each group. All elevated groups were combined into one group and all
normal groups were also combined.
Other Independent Variables
Age, sex, race/ethnicity, physical activity (PA) and smoking status were self-reported at
baseline on the personal history form. Age was categorized into four groups; 45-55, 56-65, 6675, and > 75 years of age for the descriptive results but was used as a continuous variable in the
analysis. The PA variable was dichotomized using the U.S. Department of Health and Human
Services (DHHS) PA guidelines (47); values  500 MET·min/wk were considered sufficient and
those < 500 MET·min/wk were considered insufficient. Smoking status was a calculated variable
in MESA in which participants were categorized as never smokers, former smokers or current
smokers. Family history of myocardial infarction (MI) was self-reported on the medical history
form and included any history of MI in parents, siblings, or children. Waist circumference (WC)
measurements  102 cm or  88 cm for men and women, respectively, were considered at risk.
Blood pressure (BP) was categorized into three groups: systolic blood pressure (SBP) < 120
mmHg and diastolic blood pressure (DBP) < 80 mmHg was considered normal: SBP 120-129
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mmHg and DBP < 80 mmHg elevated: and SBP > 130 mmHg or DBP ≥ 80 mmHg hypertensive.
Participants who reported anti-hypertensive medication use were also considered hypertensive.
Using the National Cholesterol Education Program Guidelines (48), triglyceride values  150
mg/dL and low-density lipoprotein values  130 mg/dL were considered elevated. High-density
lipoprotein levels < 40 mg/dL for females or < 50 mg/dL for males were considered low.
Participants who reported lipid-lowering medication use were also considered to have elevated
lipid levels. All self-reported medication use was confirmed during a medication use interview.
Anti-inflammatory medications included; oral steroids (Y/N), statins (Y/N), aspirin (Y/N), and
non-steroidal anti-inflammatory agents (excluding aspirin) (Y/N).

STATISTICAL ANALYSIS
Data was managed using SAS version 9.4 (SAS Institute, Cary, NC) (49). SAS was used
for variable recoding, coding verification, and statistical analyses. Descriptive characteristics
were obtained using the means and frequency procedures for continuous and categorical
variables, respectively. The univariate procedure was used to calculate outliers and to determine
the 75th percentile of IL-6 and sTNF-R1. SAS was used to log-transform hs-CRP following
dichotomization and IL-6 and sTNF-R1 prior to classification. Separate proportional hazards
regression models were used to calculate multivariable adjusted hazard ratios (HRs) to determine
risk of HF overall, HFrEF, and HFpEF in those with elevated hs-CRP, IL-6 and sTNF-R1
concentrations at baseline. The level of significance was set at  = 0.05 for all tests. Heart failure
participants without EF data were excluded from the subtype analyses.
After creating unadjusted and age-adjusted models, three additional models were made.
Model 1 adjusted for demographics and behavioral covariates including age, gender,
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race/ethnicity, smoking, and PA. Model 2 adjusted for the variables in Model 1 plus WC, BP,
HDL, LDL, triglycerides, and self-reported family history of MI. Model 3, the fully adjusted
model, included Model 2 covariates plus anti-inflammatory medication use including statins, oral
steroids, aspirin, and NSAIDS (excluding aspirin).
In a separate analysis using proportional hazards regression, covariates included in the
fully adjusted model were chosen using a stepwise backward elimination process. For each
model that was tested, potential covariates that did not contribute significantly based on p = 0.05
were removed and excluded from subsequent analyses. A final parsimonious model was included
to help elucidate the relationship between the independent and dependent variables.

RESULTS
During ~11.2 years of follow-up, 178 adults developed HF. Of these participants, 158
had the appropriate EF data for the subtype analysis, resulting in 87 categorized as HFrEF
(55.1%) and 71 categorized as HFpEF (44.9%). Table 1 illustrates sample characteristics
according to HF status and subtype.
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Table 1. Baseline Characteristics of U.S. Adults by HF Status
Total HF
HFrEF
Total (N=6,814)
N (%)
N (%)
Total N
178 (2.61)
87 (1.28)
Age, Mean (SD)
68.9 (8.72)
67.7 (8.99)
Age Categories
45-55
16 (8.99)
9 (10.34)
56-65
43 (24.16)
24 (27.59)
66-75
71 (39.89)
32 (36.78)
> 75
48 (26.97)
22 (25.29)
Gender
Male
106 (59.55) 61 (70.11)
Female
72 (40.45)
26 (29.89)
Race/Ethnicity
Caucasian
69 (38.76)
33 (37.93)
African American
61 (34.27)
35 (40.23)
Hispanic
38 (21.35)
17 (19.54)
Chinese
10 (5.62)
2 (2.30)
Smoking Status
Never
72 (40.68)
35 (40.70)
Former
77 (43.50)
33 (38.37)
Current
28 (15.82)
18 (20.93)
Physical Activity Level
93 (52.25)
45 (51.72)
 500 MET-min/wk
< 500 MET-min/wk
85 (47.75)
42 (48.28)
Waist Circumference (cm)
< 102, M; < 88 W
59 (33.15)
33 (37.93)
119
(66.85)
54 (62.07)
 102, M;  88 W
Blood Pressure
Normal
16 (8.99)
9 (10.34)
Elevated
10 (5.62)
3 (3.45)
Hypertensive
152 (85.39) 75 (86.21)
Family history of MI
No
84 (52.83)
34 (43.59)
Yes
75 (47.17)
44 (56.41)
Total Cholesterol (mg/dL)
75 (43.10)
37 (43.53)
LDL-C 130
87
(48.88)
41 (47.13)
TG  150
HDL-C < 40, M; < 50 W
96 (53.93)
52 (59.77)
hs-CRP
Normal
86 (56.58)
42 (53.85)
Elevated
66 (43.42)
36 (46.15)
IL-6
Normal
87 (63.04)
47 (64.38)
Elevated
51 (36.96)
26 (35.62)
sTNF-R1
Normal
35 (59.32)
15 (60.00)
Elevated
24 (40.68)
10 (40.00)
Medications
Statins
32 (17.98)
17 (19.54)

HFpEF
N (%)
71 (1.05)
70.1 (8.31)

No HF
N (%)
6,636 (97.39)
61.9 (10.20)

6 (8.45)
14 (19.72)
30 (42.25)
21 (29.58)

2130 (32.10)
1895 (28.56)
1853 (27.92)
758 (11.42)

36 (50.70)
35 (49.30)

3107 (46.82)
3529 (53.18)

29 (40.85)
20 (28.17)
15 (21.13)
7 (9.86)

2554 (38.49)
1830 (27.58)
1458 (21.97)
794 (11.97)

28 (40.00)
37 (52.11)
8 (11.27)

3346 (50.58)
2410 (36.43)
859 (12.99)

39 (54.93)
32 (45.07)

4079 (61.47)
2557 (38.53)

20 (28.17)
51 (71.83)

3032(45.69)
3604 (54.31)

5 (7.04)
6 (8.45)
60 (84.51)

2191 (33.03)
532 (8.02)
3911 (58.95)

41 (65.08)
22 (34.92)

3577 (57.36)
2659 (42.64)

28 (40.00)
35 (49.30)
34 (47.89)

3009 (45.92)
2642 (39.95)
3082 (46.46)

35 (59.32)
24 (40.68)

4235 (70.12)
1805 (29.88)

31 (60.78)
20 (39.22)

4328 (75.31)
1419 (24.69)

15 (60.00)
10 (40.00)

1900 (75.31)
623 (24.69)

11 (15.49)

977 (14.73)
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Oral Steroids
7 (3.93)
5 (5.75)
2 (2.82)
98 (1.48)
Aspirin
63 (35.39)
31 (35.63)
24 (33.80)
1639 (24.71)
NSAIDs (excluding aspirin)
31 (17.42)
21 (24.14)
9 (12.68)
1158 (17.46)
HF, heart failure; HFrEF, heart failure reduced ejection fraction (EF  50 or “Low”); HFpEF, heart
failure preserved ejection fraction (EF > 50 or “Normal”); MI, myocardial infarction; hs-CRP, high
sensitivity C-reactive protein (> 3–10 mg/L); IL-6, interleukin-6 (75th percentile); sTNF-R1, tumor
necrosis factor- receptor-1 (75th percentile); NSAID, non-steroidal anti-inflammatory drug; M; men,
W; women. Blood pressure (mmHg): Normal; SBP < 120 and DBP < 80, Elevated; SBP 120-

129 and DBP < 80, Hypertensive; SBP  130 or DBP  80; LDL-C, low-density lipoprotein;
HDL-C high-density lipoprotein; TG, triglyceride.

The prevalence of HF overall in the sample was 2.6% (1.5% of men and 1.0% of women,
p = 0.01). On average, those with HF were significantly older than those without HF, regardless
of subtype. There was a significantly greater proportion of males than females in HF overall (p =
0.01) and in HFrEF (p < 0.001), however, the same was not true for those with HFpEF (p =
0.90). There was a greater proportion of African Americans with HFrEF and a greater proportion
of Caucasians in HFpEF.
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Table 2. HRs for Incident HF, HFrEF, and HFpEF in U.S. Adults with Elevated Inflammatory
Biomarkers
HF Overall
hs-CRP
IL-6
sTNF-R1
HR
95% CI
HR
95% CI
HR
95% CI
Unadjusted
1.80***
1.31-2.49
1.83*** 1.29-2.58
2.12** 1.26-3.57
Age adjusted 1.86***
1.35-2.57
1.81*** 1.28-2.56
2.08** 1.24-3.50
Model 1
1.85***
1.32-2.58
1.66**
1.16-2.36
1.88* 1.04-3.20
Model 2
1.77**
1.23-2.54
1.56*
1.06-2.29
1.72
0.95-3.12
Model 3
1.73**
1.20-2.50
1.50*
1.02-2.22
1.64
0.93-3.06
HFrEF
hs-CRP
IL-6
sTNF-R1
HR
95% CI
HR
95% CI
HR
95% CI
Unadjusted
2.02*** 1.29-3.16
1.73*
1.07-2.80
2.07
0.93-4.61
Age adjusted
2.06*** 1.32-3.22
1.72*
1.07-2.78
2.04
0.92-4.56
Model 1
2.05**
1.29-3.26
1.49
0.91-2.44
1.68
0.73-3.88
Model 2
1.94**
1.17-3.22
1.47
0.86-2.51
1.77
0.70-4.44
Model 3
1.90**
1.14-3.15
1.39
0.81-2.38
1.69
0.67-4.24
HFpEF
hs-CRP
IL-6
sTNF-R1
HR
95% CI
HR
95% CI
HR
95% CI
Unadjusted
1.62
0.96-2.73
2.02**
1.15-3.55
2.08
0.93-4.64
Age adjusted
1.72*
1.02-2.90
2.01**
1.14-3.53
2.07
0.93-4.61
Model 1
1.79*
1.04-3.09
2.02**
1.14-3.59
2.02
0.90-4.55
Model 2
1.77
0.98-3.18
1.70
0.91-3.17
1.89
0.78-4.59
Model 3
1.76
0.97-3.18
1.69
0.90-3.16
1.96
0.81-4.75
HF, heart failure; HFrEF, heart failure with reduced ejection fraction (EF < 50 or “Low”); HFpEF,
heart failure with preserved ejection fraction (EF ≥ 50 or “Normal”); hs-CRP, high-sensitivity Creactive protein (> 3-10 mg/L); IL-6, interleukin-6 (75th percentile); sTNF-R1, soluble tumor necrosis
factor-α receptor-1 (75th percentile); HR, hazard ratio; CI, confidence interval.
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
Model 1: Adjusted for age, gender, race/ethnicity, smoking, physical activity; Model 2: Model 1 +
waist circumference, blood pressure, HDL-C, LDL-C, triglycerides, family history of myocardial
infarction; Model 3: Model 2 + statins, oral steroids, aspirin, NSAIDs (excluding aspirin)

Risk of HF
Table 2 displays the multivariable adjusted HR obtained using the proportional hazards
regression procedure for HF overall, HFrEF, and HFpEF. In the fully adjusted model,
participants with elevated hs-CRP had a significantly greater risk of HF overall (HR 1.73; 95%
Confidence Interval [CI] 1.20-2.50; p ≤ 0.01). In those with elevated IL-6, the risk of HF overall
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was attenuated after controlling for covariates but remained statistically significant in the in the
fully adjusted model (HR 1.50; 95% CI 1.02-2.22; p < 0.05). In the age-adjusted model, adults
with elevated sTNF-R1 concentrations had a significantly greater risk of HF overall however,
after adjusting for anti-inflammatory medications, this relationship was borderline significant (p
= 0.06).
Table 3 includes the HRs of HF overall in the parsimonious models. In this analysis,
elevated hs-CRP, IL-6 and sTNF-R1 were all significantly associated with an increased risk of
HF overall with the greatest risk seen in elevated sTNF-R1 (HR 1.91; 95% CI 1.08-3.38; p <
0.05). Females had a significantly lower risk of HF compared to males with the lowest risk seen
in the hs-CRP model (HR 0.43; 95% CI 0.29-0.64; p ≤ 0.001). Self-reported smokers had a twotime greater risk of HF whereas those who were hypertensive at baseline showed a three to fourtime greater risk of HF in all three models. Overall, the significant contributors seen across all
three models were the same apart from PA in IL-6, and WC and oral steroids in sTNF-R1, which
did not significantly contribute to either model.
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Table 3. HRs for Incident HF in U.S. Adults with Elevated Inflammatory Markers
hs-CRP
IL-6
sTNF-R1
HR
95% CI
HR
95% CI
HR
95% CI
Biomarker
Elevated
1.76 1.22-2.52**
1.57 1.07-2.30*
1.91 1.08-3.38*
Age
1.07 1.04-1.09*** 1.07 1.04-1.09*** 1.09 1.06-1.13***
Gender
Male
Female
0.43 0.29-0.64*** 0.47 0.31-0.70*** 0.54 0.30-0.99*
Smoking Status
Never
Former
1.07 0.72-1.58
1.21 0.81-1.82
0.99 0.52-1.91
Current
2.24 1.35-3.70**
2.50 1.45-4.33*** 2.92 1.30-6.57**
Blood Pressure
Normal
Elevated
1.50 0.56-4.01
2.22 0.76-6.42
2.90 0.71-11.77
Hypertensive
3.16 1.71-5.83**
4.35 2.08-9.09*** 4.03 1.41-11.51**
Physical Activity Level
 500 MET-min/wk
< 500 MET-min/wk 1.44 1.01-2.04*
1.96 1.19-3.45**
Waist Circumference (cm)
< 102, M; < 88 W
1.54 1.05-2.28*
1.62 1.08-2.43**
 102, M;  88 W
Medications
Oral Steroids
2.50 1.09-5.73*
3.33 1.45-7.63**
HF, heart failure; hs-CRP, high sensitivity C-reactive protein (> 3-10 mg/L); IL-6, interleukin-6
(75th percentile); sTNF-R1, soluble tumor necrosis factor-α receptor-1 (75th percentile); HR,
hazard ratio; CI, confidence interval; M; men, W; women. Blood pressure (mmHg): Normal;
SBP < 120 and DBP < 80, Elevated; SBP 120-129 and DBP < 80, Hypertensive; SBP  130 or
DBP  80. *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
Risk of HFrEF
In the fully adjusted model, participants with elevated hs-CRP had a significant increased
risk of HFrEF (HR 1.90; 95% CI 1.14-3.15; p ≤ 0.01) (Table 2). For those with elevated baseline
IL-6 concentrations, the age-adjusted model revealed a significant 72% increased risk of HFrEF
(HR 1.72; 95% CI 1.07-2.78; p < 0.05), however, this relationship did not remain statistically
significant in the fully adjusted model. Elevated sTNF-R1 was not significantly associated with
risk of HFrEF in any model.

77
Table 4 includes the HRs of HFrEF in the parsimonious models. Elevated hs-CRP was
associated with a significant two-time greater risk of HFrEF (HR 2.05; 95% CI 1.26-3.35; p ≤
0.01). For IL-6, when the smoking status variable was added to the model the relationship was
attenuated and longer statistically significant, so the model was stratified by never smokers and
current or former smokers. This revealed that for smokers or former smokers, IL-6 did not
significantly contribute to the model, however, for never smokers it did (HR 1.71; 95% CI 0.883.32; p > 0.05, and HR 2.33; 95% CI 1.04-5.23; p < 0.05, respectively). Elevated sTNF-R1 was
not significantly associated with risk of HFrEF in any model (data not shown).

Table 4. HRs for Incident HFrEF in U.S. Adults with Elevated Inflammatory Markers
hs-CRP
IL-6
Never Smokers
Ever Smokers
HR
95% CI
HR
95% CI
HR
95% CI
Biomarker
Elevated
2.05 1.26-3.35**
2.33
1. 04-5.23*
1.71 0.88-3.32
Age
1.04 1.02-1.07***
1.06
1.02-1.10**
1.05 1.01-1.09**
Gender
Male
Female
0.28 0.16-0.49***
0.29
0.12-0.67**
0.25 0.10-0.61**
Medications
Oral Steroids
4.80 1.91-12.06*** 8.81
1.99-38.98**
Smoking Status
Never
Former
0.91 0.52-1.60
Current
2.71 1.43-5.13**
Family hx
No
Yes
1.89 1.16-3.07**
Blood Pressure
Normal
Elevated
0.88 0.18-4.28
Hypertensive
3.38 1.51-7.55**
HFrEF, heart failure with reduced ejection fraction (EF < 50 or “Low”); hs-CRP, highsensitivity C-reactive protein (> 3-10 mg/L); IL-6, interleukin-6 (75th percentile); HR, hazard
ratio; CI, confidence interval; M; men, W; women. Blood pressure (mmHg): Normal; SBP <
120 and DBP < 80, Elevated; SBP 120-129 and DBP < 80, Hypertensive; SBP  130 or DBP
 80. *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
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Risk of HFpEF
Those with elevated hs-CRP had a borderline 76% increased risk of HFpEF in the fully
adjusted model (HR 1.76; 95% CI 0.97-3.18; p = 0.06). In IL-6 the age-adjusted model revealed
a significant increased risk of HFpEF (HR 2.05; 95% CI 1.17-3.60; p = 0.01), however, after
adjusting for WC this relationship did not remain statistically significant. Elevated sTNF-R1 was
not significantly associated with risk of HFpEF in any model.
Table 5 includes the HRs of HFpEF in the parsimonious models. Elevated hs-CRP was
associated with a significant 89% increased risk of HFpEF and nearly a five-times greater risk in
hypertensive individuals compared to their normotensive counterparts. For IL-6, when the
race/ethnicity variable was added to the model, the relationship was no longer significant, so the
model was stratified by race/ethnicity. This revealed that African Americans with elevated IL-6
had almost a six-time significantly greater risk of HFpEF (HR 5.89; 95% CI 1.52-22.80; p ≤
0.01). There was not a significant relationship seen with elevated IL-6 in Caucasians, Hispanics,
or Chinese Americans (data not shown). Elevated sTNF-R1 was not significantly associated with
risk of HFrEF in any model (data not shown).
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Table 5. HRs for Incident HFpEF in U.S. Adults with Elevated Inflammatory
Markers
hs-CRP
IL-6
African Americans
HR 95% CI
HR
95% CI
Inflammatory Biomarker
Elevated
1.89 1.09-3.28*
5.89 1.52-22.80**
Age
1.09 1.05-1.13*** 1.09 1.02-1.17**
Blood Pressure
Normal
Elevated
2.83 0.56-14.13
Hypertensive
4.73 1.44-15.51**
HFpEF, heart failure with preserved ejection fraction (EF ≥ 50 or “Normal”);
hs-CRP, high-sensitivity C-reactive protein (> 3-10 mg/L); IL-6, interleukin-6
(75th percentile); HR, hazard ratio; CI, confidence interval. Normal; SBP <
120 and DBP < 80, Elevated; SBP 120-129 and DBP < 80, Hypertensive;
SBP  130 or DBP  80 *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001

DISCUSSION
Recent reports (11, 26, 50) have addressed the need for investigating the novel use of
biomarkers in the evaluation and management of HF patients. In this multi-ethnic, populationbased sample, elevated hs-CRP (> 3-10 mg/L), IL-6 (> 75th percentile) and sTNF-R1 (> 75th
percentile) were associated with a significant increase in risk of HF. When examining risk by HF
subtype, hs-CRP was a significant predictor in both HFrEF and HFpEF. Interestingly, baseline
IL-6 concentrations were a significant predictor of HFrEF in nonsmokers only and of HFpEF in
African Americans only. These findings add to the evidence demonstrating a positive
relationship between biomarkers of inflammation in HF (32, 35, 51) and to the risk differences
seen in HFrEF and HFpEF (17).
Many studies that have examined the associations between biomarkers of inflammation
and HF have either included only those with HFrEF or did not stratify by HF subtype at all (28,
32, 35, 36). In a 2018 study (52), DuBrock et al. investigated the relationship between CRP and
HFpEF (≥ 50%) in 216 outpatients with objective evidence of HF. They reported that CRP was
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elevated in about 60% of patients in this sample, which is much higher than in our study (40%).
This is likely because our sample was free from clinical cardiovascular disease at baseline when
CRP values were measured whereas DuBrock et al.’s analysis measured CRP values in HF
patients, who are already more likely to have elevated CRP (51).
Our findings also add to the research examining the race/ethnicities differences in HF and
the HF subtypes, the latter being much less established. In a 2005 community cohort study (6),
Galasko et al. examined ethnic differences in the prevalence and etiology of LV systolic
dysfunction in 734 patients ≥ 45 years of age. The investigators found a similar overall
prevalence of LV systolic dysfunction among white and non-white participants. However,
though the aim was to examine ethnic differences, the sample was primarily white (71%) and the
majority of the non-white patients were South Asian, which are more likely to have LV diastolic
dysfunction (53).
In a 2008 study (32), Bahrami et al. examined race/ethnicity differences in 79 incident
CHF patients after a median 4.0 years of follow-up in the MESA. African Americans were found
to have the highest incidence rates of CHF and the greatest risk of developing CHF, however,
this relationship was no longer significant after adjusting for hypertension and/or diabetes.
Interestingly, African Americans had the highest proportion of CHF that was not preceded by
clinical MI (p = 0.06). This is interesting because African Americans have the greatest risk of MI
(54) and of the two HF subtypes, previous MI is a significantly stronger risk factor for HFrEF
than HFpEF (17). The present study revealed a significant increased risk of HFpEF in African
Americans with elevated IL-6 but not any other race/ethnicity. Studies that have examined IL-6
across difference race/ethnicities have been contradicting (55, 56) and this relationship warrants
further investigation.
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The predictive value of IL-6 in HFrEF was dependent on smoking status in this analysis.
This is interesting since both IL-6 and smoking are associated with inflammation in HF patients
(57, 58). Cigarette use is a well-known, strong risk factor in HFrEF, but in nonsmokers, there
may be indication for IL-6 to take its place in predicting risk according to our analysis. The
Health, Aging, and Body Composition Study (59), examined the predictive value of CRP, TNFα, and IL-6 in incident HF. The investigators reported that adding IL-6 to their risk prediction
model improved the performance of the model.
Due to the sequential discovery of HFrEF and HFpEF, many early clinical trials only
included those with HFrEF and the life-prolonging therapies that have been successfully
implemented over the past 30 years in this subtype have not been efficacious for those with
HFpEF (13). In the 2016 guidelines for the diagnosis and treatment of acute and chronic HF (13),
the European Society of Cardiology stated that no treatment to date has convincingly been shown
to reduce morbidity or mortality in HFpEF patients. Current treatment recommendations for
HFpEF focus on managing comorbidities and alleviating symptoms, however, there is emerging
evidence that inflammation might be the target for prevention intervention
(14, 59). Cytokines themselves may be a potential therapeutic target in some patients (60),
however, in the prevention of HF, the role of lifestyle behaviors should also be considered.
Greater achievement of the AHA’s Life’s Simple 7 guidelines (61) on smoking, body mass, PA,
diet, cholesterol, BP, and glucose has been associated with a lower lifetime risk of HF as well as
preservation of cardiac structure and function in old age. In the present study, PA levels
significantly added the hs-CRP and sTNF-R1 models. Additionally, insufficient PA (< 500
MET·min/wk) in accordance to the 2018 DHHS PA guidelines (47) was also associated with an
increased risk of HF overall. Chronic exercise training has been shown to have anti-
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inflammatory effects, independent of body fat loss, in adults of any age and even with chronic
conditions including HF and type 2 diabetes (62). Even acute 20-min bouts of exercise have been
shown to decrease inflammatory responses via down regulation of TNF-α (63).
In a 2019 study, Upadhya et al. (14) reviewed several non-pharmacological interventions
that have been done in HFpEF including exercise interventions. Despite exercise intolerance
being a cardinal sign in HF, the exercise interventions revealed several positive outcomes
including increased exercise capacity, peak oxygen consumption, quality of life and even
diastolic dysfunction. Additionally, this review provides an exercise prescription for those with
stable HFpEF, which could prove useful for clinicians working with HFpEF patients.
Considering the lack of effective therapies in HFpEF, this evidence underscores the importance
of PA in reducing inflammation and in the prevention and treatment of HF.
There are a few limitations to this study. Inherent to the design of the MESA to create an
ethnically diverse sample, the sample is not representative of US adults, thus affecting the
external validity of the results. Additionally, biomarkers of inflammation were measured at a
single time point, therefore, it is unclear if elevated concentrations were indicative of acute or
chronic inflammation. However, all outliers were excluded, and serial measurements of these
biomarkers have been shown to add little information (64). Another limitation of this study is the
small sample size among the HF samples. Additionally, only a subset of the population had
measured sTNF-R1 values, which contributed to the lack of significant findings seen in this
biomarker when stratified by HF subtype. Incident HF was defined as time to first HF event,
therefore subsequent HF events and potential changes in EF over time were not included in the
analysis.
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In summary, the results of this study suggested that elevated hs-CRP, IL-6 and sTNF-R1
are positively associated with HF risk. Elevated hs-CRP was also positively associated with risk
of HFrEF and HFpEF. Elevated IL-6 predicted HFrEF among nonsmokers only and HFpEF in
African Americans only. Further research is necessary to determine the pathophysiological
mechanisms behind these findings and to further elucidate the associations between HFrEF and
HFpEF. The combined use of various biomarkers in determining the prognosis and diagnosis of
HF should also be examined.
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